Healthpeak Properties vs H&M (Hennes & Mauritz)

About

Healthpeak Properties, Inc. is a Denver, Colorado-based healthcare real estate investment trust — publicly traded on the New York Stock Exchange (NYSE: DOC) as an S&P 500 Real Estate component — owning, operating, and developing healthcare-focused real estate including life science laboratory buildings (biopharmaceutical R&D facilities in South San Francisco, San Diego, Boston), medical office buildings (outpatient care facilities adjacent to major hospital campuses), and continuing care retirement communities through approximately 400 employees. In March 2024, Healthpeak Properties (then trading as HCP/PEAK) completed its $21 billion merger of equals with Physicians Realty Trust (DOC — medical office REIT with 300+ medical outpatient buildings in 30+ states) — adopting Physicians Realty Trust's ticker symbol "DOC" and creating a $21 billion combined healthcare REIT with 60+ million square feet of life science labs, 18+ million square feet of medical office, and the most diversified healthcare real estate portfolio among public healthcare REITs. CEO Scott Brinker leads the combined company's strategy of capitalizing on the structural demand drivers for healthcare real estate: life science lab demand driven by NIH funding, private biopharma venture investment, and drug approval tailwinds — and medical office demand driven by the shift of healthcare delivery from hospital inpatient settings to outpatient ambulatory care facilities that require real estate closer to patient populations. Healthpeak's life science portfolio in the three dominant biotech clusters (San Francisco Bay Area, San Diego's Torrey Pines/UTC corridor, Boston's Kendall Square/Route 128 corridor) positions it in the markets where biopharma and biotech tenants require Class A laboratory space for drug discovery and development.